Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy
- PMID: 34007941
- PMCID: PMC8099667
- DOI: 10.1253/circrep.CR-20-0101
Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy
Abstract
Background: Although atrial fibrillation (AF) is a well-known risk factor for embolic stroke in hypertrophic cardiomyopathy (HCM), there is a paucity of information derived from HCM patients who have experienced embolic stroke. Methods and Results: From 141 consecutive HCM patients who had been hospitalized between 2000 and 2018, the clinical characteristics and management of 86 patients with AF were analyzed retrospectively. The incidence of embolic stroke was 36% (n=31 patients). The median (interquartile range) age of embolic stroke was younger in male than female HCM patients (71 [64-80] vs. 83 [77-87] years, respectively; P=0.009). The prevalence of paroxysmal AF (74%) was significantly higher than that of chronic AF (26%) in 31 patients with embolic stroke (P=0.007). The CHADS2 score in patients with embolic stroke was not particularly useful in predicting the occurrence of embolic stroke. Conclusions: One-third of HCM patients with AF developed embolic stroke, and male HCM patients were younger at the time of the embolic stroke than female HCM patients. The prevalence of paroxysmal AF was significantly higher than that of chronic AF in patients with AF and embolic stroke. Early introduction of anticoagulation therapy is recommended at the first documentation of paroxysmal AF.
Keywords: Embolic stroke; Hypertrophic cardiomyopathy; Paroxysmal atrial fibrillation; Sex difference.
Copyright © 2021, THE JAPANESE CIRCULATION SOCIETY.
Conflict of interest statement
H.K. is a member of Circulation Reports’ Editorial Team. The remaining authors declare no conflicts of interest.
Figures



Similar articles
-
Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation.Stroke. 2016 Apr;47(4):936-42. doi: 10.1161/STROKEAHA.115.012130. Epub 2016 Mar 3. Stroke. 2016. PMID: 26941260
-
Clinical significance of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy.ESC Heart Fail. 2021 Dec;8(6):5022-5030. doi: 10.1002/ehf2.13563. Epub 2021 Sep 2. ESC Heart Fail. 2021. PMID: 34472710 Free PMC article.
-
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.Circulation. 2017 Dec 19;136(25):2420-2436. doi: 10.1161/CIRCULATIONAHA.117.029267. Epub 2017 Sep 15. Circulation. 2017. PMID: 28916640
-
Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?Clin Res Cardiol. 2015 Oct;104(10):799-802. doi: 10.1007/s00392-015-0876-6. Epub 2015 Jul 2. Clin Res Cardiol. 2015. PMID: 26133157 Review.
-
Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation.Front Cardiovasc Med. 2023 Apr 17;10:1023394. doi: 10.3389/fcvm.2023.1023394. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37139132 Free PMC article. Review.
Cited by
-
A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants.JACC Basic Transl Sci. 2022 Aug 10;7(8):763-775. doi: 10.1016/j.jacbts.2022.04.008. eCollection 2022 Aug. JACC Basic Transl Sci. 2022. PMID: 36061336 Free PMC article.
-
Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy.Egypt Heart J. 2025 Jun 13;77(1):61. doi: 10.1186/s43044-025-00652-0. Egypt Heart J. 2025. PMID: 40512253 Free PMC article. Review.
References
-
- Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al.. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implication on the projections for future prevalence. Circulation 2006; 114: 119–125. - PubMed
-
- Kirchhof P, Benussi K, Kotecha D, Ahlsson A, Atar D, Casadei B, et al.. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–2962. - PubMed
-
- Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, et al.. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the Netherlands. J Am Coll Cardiol 2015; 66: 1000–1007. - PubMed
-
- Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ.. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104: 2517–2524. - PubMed
-
- Doi Y, Kitaoka H.. Hypertrophic cardiomyopathy in the elderly: Significance of atrial fibrillation. J Cardiol 2001; 37(Suppl 1): 133–138. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources